US health regulator says heart devices recall “most serious”
A recall of Swedish makers' of heart devices has been classified by the FDA as "most serious" since they could lead to severe.
Drugs
Medical
Pharma
Drugs
Pharma
Eli Lilly plans $450 million extra to expand Research Triangle
Eli Lilly will invest an additional $450 million to expand its manufacturing capacity at Research Triangle Park facility in North Carolina.
Drugs
Pharma
WHO urges “immediate” action on falsified medicines
The WHO called on stakeholders in various nations to take “immediate and coordinated action” to shield children from using contaminated cough syrups following.
Drugs
Pharma
Merck says it has identified the cause of contamination of its diabetes medicines
Merck says its diabetes drugs got contaminated during storage and manufacturings and it will improve the same to prevent it in future
Drugs
Pharma
Johnson & Johnson pulls out of HIV phase III trial
Johnson & Johnson stopped the phase III trial of its global HIV vaccine trial after it found that the regimen was ineffective in.
Drugs
Pharma
India bolsters regulators to brace global competition
India is bolstering its regulatory bodies to global standards to become a world leader in drug discovery and innovative medical devices, a minister.
Drugs
Pharma
Glenmark’s heart failure treatment drug makes India debut
Glenmark Pharmaceuticals, an Indian multinational firm, has introduced its heart failure drug in the country, according to a company statement.
Drugs
Pharma
US regulatory nod for Lupin’s HIV drug in the works
Pharma major Lupin has received a ‘tentative approval’, from the United States Food and Drug Administration (FDA), to market medicines used to treat.
Drugs
Pharma
USFDA grants ‘tentative approval’ to Zydus’ mental health drug
The USFDA has granted Zydus Lifesciences Limited ‘tentative approval’ to market Levomilnacipran extended-release capsules in 20 mg, 40 mg, 80 mg, and 120.
Drugs
Pharma
Eiasi files market authorization for Alzheimer’s drug in Japan
Eiasi Co., a Japanese pharmaceutical company, has submitted a marketing authorization application for a drug, lacanemab, to treat Alzheimer's disease.